Seasoned commercial leader to oversee hybrid commercial organization
and upcoming launch of Bone Repair Surgical Therapy in the U.S.
BEDFORD, Mass.--(BUSINESS WIRE)--Apr. 30, 2019--
Therapeutics, Inc. (NASDAQ: ANIK), a global, integrated orthopedic
and regenerative medicines company specializing in therapeutics based on
its proprietary hyaluronic
acid ("HA") technology, today announced the appointment of
Stephen Goldy to the newly created position of Vice President of U.S.
Sales. Mr. Goldy brings over 20 years of experience developing and
implementing sales strategy, with a specialization in the orthopedic,
sports medicine and general surgery markets. In this new role, Mr. Goldy
will oversee sales strategy and operations for the Company’s hybrid
commercial organization in the United States.
“Stephen is an important addition to our team as we establish and
execute our new hybrid commercial organization in the U.S.,” said Joseph
Darling, President and Chief Executive Officer of Anika Therapeutics.
“Stephen brings more than two decades of sales experience and a deep
understanding of the orthopedic surgery and sports medicine markets,
which will be critical to our near- and long-term growth. We look
forward to benefitting from his knowledge and expertise as we prepare
for the launch of our first surgically-delivered regenerative therapy
for bone repair procedures in the U.S. in the second half of this year.
His proven track record of defining and exceeding sales targets and
cultivating and managing national accounts will be invaluable as we
transform Anika into a global commercial company.”
“I am very excited to join Anika at this transformational time in its
evolution and look forward to developing and implementing its hybrid
commercial model in advance of the upcoming launch of the Company’s bone
repair product in the U.S.,” said Stephen Goldy, Vice President of U.S.
Sales at Anika Therapeutics. “Anika’s deep orthopedic and regenerative
medicine pipeline and solid reputation for high-quality, innovative
treatments positions the company for its next phase of growth.”
Prior to joining Anika, Mr. Goldy spent seven years at ConMed
Orthopedics, a global medical device manufacturer, as Regional Vice
President and Director of Sales. Before joining ConMed, Mr. Goldy served
as National Accounts Manager for Creekridge Capital, a privately-held
equipment leasing company, and Global Financial Services Manager at
Smith and Nephew. Mr. Goldy holds a Master of Business Administration
and Bachelor of Science from the University of Massachusetts.
About Anika Therapeutics, Inc.
Therapeutics, Inc. (NASDAQ: ANIK) is a global, integrated
orthopedic and regenerative medicines company based in Bedford,
Massachusetts. Anika is committed to improving the lives of patients
with degenerative orthopedic diseases and traumatic conditions with
clinically meaningful therapies along the continuum of care, from
palliative pain management to regenerative tissue repair. The Company
has over two decades of global expertise developing, manufacturing, and
commercializing more than 20 products based on its proprietary hyaluronic
acid (HA) technology. Anika's orthopedic medicine portfolio
includes ORTHOVISC®, MONOVISC®,
which alleviate pain and restore joint function by replenishing depleted
HA, and HYALOFAST,
a solid HA-based scaffold to aid cartilage repair and regeneration. For
more information about Anika, please visit www.anikatherapeutics.com.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190430006019/en/
Source: Anika Therapeutics, Inc.
For Investor Inquiries:
Anika Therapeutics, Inc.
Chief Financial Officer
For Media Inquiries:
Sonal Vasudev, 917-523-1418